Furthermore, a multi-peptide cancer vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF) is currently undergoing a phase I/II study in patients with advanced melanoma (Perales et al., 2008). This evidence concerns the gene CSF2 and melanoma.